AHMEDABAD: An increasing number of firms are rushing to manufacture hydroxychloroquine (HCQ), the anti-malarial drug being used widely in the treatment of Covid-19 patients across the world, and now India, too.
The Food and Drug Control Administration (FDCA) of Gujarat issued permits to 68 pharmaceutical firms to manufacture HCQ tablets in the state. “In past one and a half months, 68 pharmaceutical companies have received product licences to make HCQ tablets of varied dosages in Gujarat,” HG Koshia, commissioner of Gujarat FDCA, said.
Companies like Sun Pharma, Intas Pharmaceuticals, Saga Lifesciences Limited, Norris Medicines, Ellis Pharmaceuticals, Jaimin Remedies, and Lincoln Pharma have received approvals for producing HCQ tablets.
“In 60 years before Covid-19 outbreak, Gujarat had only 28 companies manufacturing HCQ tablets. The number has jumped three-times in less than two months’ time. Now, state has 96 players making this drug,” Koshia said.HCQ is currently the most preferred drug in Covid-19 management globally,” Viranchi Shah, MD of Saga Lifesciences Limited, said.
India is a major source of HCQ supply and meets 70% of the world requirement.